DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for disorder of sexual differentiation — screening already-approved drugs against its 26-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDisorder of sexual differentiation maps to a 26-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for disorder of sexual differentiation is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome p450 oxidoreductase (POR) — POR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet faddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3QE2 · 1.75 Å · ligand FLAVIN-ADENINE DINUCLEOTIDE (FAD). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Sex Education and Therapy · 1992 · 6 citations
Reversal of Doxepin-Induced Hypoactive Sexual Desire By Substitution Of Nortriptyline
AbstractAlthough there are many reports of female anorgasmia as a side effect of tricyclic antidepressants, less has been written in regard to hypoactive sexual desire disorder. A case is presented of a 44-year-old woman who developed hypoactive sexual desire (sexual indifference) when placed on Doxepin. After her prescription was changed to Nortriptyline, her sexual desire returned. This change in sexual desire may have been due to Doxepin being more anticholinergic, considerably more serotonergic, or slightly less adrenergic than Nortriptyline.
The Clinical Use of Stilboestrol for Suppression of Sexual Behaviour of Chronically Ill Male Psychiatric Patients
AbstractIn view of the significant role the sexual instinct plays in psychiatric illness, it is surprising that there are in the literature so few reports of attempts to suppress male sexual behaviour by the direct method of modifying the physiological basis of sexual activity by oestrogen therapy. Dunn (2, 3) established that administration of stilboestrol could result in marked reduction of male libido and sexual behaviour. He treated two non-psychotic hypersexual patients and, apart from the clinical effects, observed gynaecomastia, histological evidence of reversible testicular degeneration, and depressed urinary androgen excretion. Hamburger (6) later demonstrated in one case that oestradiol administration produced the same degree of urinary androgen excretion as did actual surgical castration of the same patient. Thus, present evidence indicates that oestrogen therapy produces in the male what is, in effect, a reversible chemical castration.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
